PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) – 1986

The medicine is dispensed with a doctor's prescription only.

Zavesca®

Capsules

The active ingredient and its quantity

Each capsule contains:

Miglustat 100 mg

For a list of inactive ingredients in the preparation, see section 6 "Further Information".

Read the leaflet carefully in its entirety before using the medicine. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist.

This medicine has been prescribed for the treatment of your ailment. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar.

This medicine is not intended for children and adolescents below 18 years of age with type 1 Gaucher disease.

1. WHAT IS THE MEDICINE INTENDED FOR?

- Treatment of mild to moderate type 1 Gaucher disease in patients who have been found unsuitable for enzyme replacement therapy.
- Treatment of progressive neurological symptoms in adults and children who suffer from Niemann-Pick type C disease.

Therapeutic group: An enzyme inhibitor that affects metabolism.

2. BEFORE USING THE MEDICINE

Do not use the preparation if:

- You are sensitive (allergic) to the active ingredient (miglustat) or any of the additional ingredients of the medicine.
- Do not use the medicine if you are pregnant or breastfeeding.

Special warnings regarding use of the medicine

- **Before beginning treatment with Zavesca, tell the doctor if:**
  - You suffer from kidney disease.
  - You suffer from liver disease.
  - You are sensitive to any food or any medicine.
- If you suffer from diarrhea, your doctor may recommend a change in your diet to lower the amount of lactose and carbohydrates consumed (such as sucrose), or not to take Zavesca together with food, or to temporarily reduce your dose. In some cases your doctor may consider giving an anti-diarrheal medicine such as loperamide. If the diarrhea is not relieved by these measures, or if you suffer from another problem in your digestive system, consult your doctor. In such case, your doctor may decide to conduct further investigation.
- Male patients must use reliable birth control methods during the course of treatment with Zavesca, and for 3 months after finishing treatment.

Tests and follow-up

Before and during treatment with this medicine, the doctor will refer you to perform the following tests:

- An examination of nerves in the hands and feet
- Measurement of vitamin B12 levels
- Monitoring growth in children and adolescents with Niemann-Pick type C disease
- Monitoring of blood platelet count

The reason for these tests is that some patients may experience numbness or tingling in the hands and feet, or weight loss, during the course of treatment with the medicine. The tests will help the doctor decide whether these effects are due to your disease, due to other existing problems, or due to side effects of Zavesca (see section 4 "Side Effects").

Drug interactions

If you are taking, or have recently taken, other medicines, including non-prescription medicines and nutritional supplements, tell the doctor or pharmacist. In particular if you are taking:

- Medicines containing imiglucerase, which are sometimes given together with Zavesca, may lower the amount of Zavesca in your body.

Use of the medicine and food

The medicine may be taken with or without food.

Pregnancy, breastfeeding and fertility

Do not use Zavesca if you are pregnant or planning to become pregnant. You must use effective birth control methods during the course of treatment with Zavesca.

Do not breastfeed during treatment with Zavesca.

Male patients must use reliable birth control methods during the course of treatment with Zavesca, and for 3 months after finishing the treatment.

If you are pregnant, breastfeeding, think you may be pregnant or planning to become pregnant, ask your doctor for advice before using this medicine. Your doctor will be able to give you more information.

Use in children

The medicine is not intended for children and adolescents below 18 years of age with type 1 Gaucher disease.

Driving and operating machinery

Using this medicine may cause dizziness. Therefore, do not drive or operate dangerous machinery if you feel dizzy.

Important information about some of the ingredients of the medicine

Sodium

This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 'sodium-free'.

3. HOW SHOULD THE MEDICINE BE USED?

- Always use the medicine according to the doctor's instructions. Check with the doctor or pharmacist if you are uncertain.

The dosage and treatment regimen will be determined by the doctor only. The usual dose is generally:

- For type 1 Gaucher disease
  Adults: The dose is generally one capsule (100 mg) three times a day (morning, afternoon and evening). The maximum amount is three capsules (300 mg) per day.
- For Niemann-Pick type C disease
  Adults and adolescents (over 12 years of age): The dose is generally two capsules (200 mg) three times a day (morning, afternoon and evening). The maximum amount is six capsules (600 mg).
  Children less than 12 years of age: Your doctor will adjust the dose.

If you suffer from a problem with your kidneys, you may be prescribed a lower starting dose. If you suffer from diarrhea while taking Zavesca, your doctor may consider reducing your dose, e.g., to one capsule (100 mg) once or twice a day (see section 2 "Special warnings regarding use of the medicine"). Your doctor will explain to you how long your treatment will last.

Do not exceed the recommended dosage.

- The medicine may be taken with or without food.
- Swallow the capsules whole with a glass of water.

Opening instructions:

To remove the capsule:

1. Separate along the perforated line
2. Peel back the paper as indicated by the arrows
3. Push the capsule through the foil



If you accidentally took an overdose, or if a child has accidentally swallowed the medicine, refer immediately to a doctor or proceed to a hospital emergency room, and bring the package of the medicine with you.

During the use of Zavesca in clinical trials at doses ten times higher than the recommended dose, a decrease in white blood cells was observed, as well as other side effects similar to those described in section 4 of this leaflet.

If you forgot to take this medicine at the required time, take the next dose at the regular time and consult the doctor. Do not take a double dose to make up for a forgotten dose. Adhere to the treatment regimen as recommended by the doctor.

If you stop taking the medicine

Do not stop the treatment without consulting the doctor.

Do not take medicines in the dark! Check the label and the dose each time you take medicine. Wear glasses if you need them.

If you have further questions regarding use of the medicine, consult the doctor or pharmacist.

4. SIDE EFFECTS

As with any medicine, use of Zavesca may cause side effects in some users. Do not be alarmed by the list of side effects. You may not suffer from any of them.

Refer to the doctor immediately if any of the following side effects occur:

- The most serious side effects:
  Some patients may have tingling or a pins-and-needles sensation in the hands and feet (seen commonly). These effects may be signs of peripheral nerve disease (neuropathy), due to side effects of Zavesca or due to existing diseases. Your doctor will refer you to perform some tests before and during treatment with Zavesca to assess this (see section 2 "Tests and follow-up").
- If you feel a slight tremor, usually in the hands, refer to your doctor as soon as possible. In most cases, the tremor disappears without needing to stop the treatment, but sometimes your doctor will consider reducing the dose or stopping Zavesca treatment to stop the tremor.

Additional side effects

Very common side effects – affect more than 1 patient in 10:
Diarrhea, bloated abdomen (flatulence), abdominal pain, weight loss, decreased appetite.
Do not worry if you lose weight when starting Zavesca treatment. This effect usually stops in patients as treatment goes on.

Common side effects – affect up to 1 patient in 10:
Headaches, dizziness, pins-and-needles sensation or tingling, impaired coordination, reduced sense of touch, heartburn, nausea, constipation, vomiting, bloating or discomfort in the stomach, reduced level of blood platelets (thrombocytopenia). The neurological symptoms and the reduced level of blood platelets could be caused by the disease itself.

Other side effects include muscle spasms, muscle weakness, fatigue, chills and malaise, depression, insomnia, memory loss, reduced libido.

Most patients experience one or more of the effects mentioned above, usually at the start of treatment or at intervals during treatment. In most cases, these effects are mild and disappear relatively quickly. If these effects cause problems, refer to your doctor. Your doctor will consider reducing the dose of Zavesca, or alternatively, recommending other medicines to treat these side effects.

If a side effect occurs, if one of the side effects worsens or if you suffer from a side effect not mentioned in the leaflet, consult with the doctor.

Side effects can be reported to the Ministry of Health by clicking on the link "Report Side Effects of Drug Treatment" found on the Ministry of Health homepage (www.health.gov.il) that directs you to the online form for reporting side effects, or by entering the link:

https://sideeffects.health.gov.il

5. HOW SHOULD THE MEDICINE BE STORED?

- Avoid poisoning! This medicine, and any other medicine, should be kept in a safe place out of the reach and sight of children and/or infants in order to avoid poisoning. Do not induce vomiting unless explicitly instructed to do so by the doctor.
- Do not use the medicine after the expiry date that appears on the package. The expiry date refers to the last day of that month.
- Store at a temperature below 30°C.
- Do not throw away medicines via wastewater or in the rubbish. Ask the pharmacist how to discard medicines that are not in use. These measures will help protect the environment.

6. FURTHER INFORMATION

In addition to the active ingredient, the medicine also contains:

Sodium starch glycollate, povidone (K30), magnesium stearate, gelatin, water, titanium dioxide (E171), black iron oxide (E172), shellac.

What the medicine looks like and contents of the package

White capsules with "OGT 918" marked in black on the cap and "100" marked in black on the capsule body.

The medicine is packaged in boxes of 4 trays (blisters); each tray contains 21 capsules – a total of 84 capsules.

Importer and Registration Holder and address:

J-C Health Care Ltd., Kibbutz Shefayim 6099000, Israel.

Registration number of the medicine in the National Drug Registry of the Ministry of Health:

128 34 30714 00

Revised in March 2021 according to MOH's guidelines.